Skip to main content

Table 2 The increase in drug demand during COVID-19 in Yemen as perceived by participants (N = 330)

From: Changes in drug demand when a pandemic coincides with other outbreaks in a war zone country: a cross-sectional pilot study

Drug demand by pharmacological category

% (n)

1. Antibiotics

 

 No, the demand did not change

4.8 (16)

 Yes, the demand increased

95.2 (314)

- Macrolides

90.6 (299)

- Parenteral cephalosporins

78.5 (259)

- Penicillin

60.6 (200)

- Oral cephalosporins

58.8 (194)

- Fluoroquinolone

0

- Aminoglycosides

0

2. Analgesics and antipyretics

 

 No, the demand did not change

1.2 (4)

 Yes, the demand increased

98.8 (326)

- Oral paracetamol

90.9 (300)

- Parenteral paracetamol

90.3 (298)

- Paracetamol–codeine combinations

74.8 (247)

- Parenteral diclofenac

44.5 (147)

- Oral diclofenac

26.1 (86)

- Oral ibuprofen

24.2 (80)

- Oral meloxicam

17.0 (56)

- Parenteral meloxicam

7.3 (24)

- Oral tramadol

10.6 (35)

- Parenteral tramadol

4.8 (16)

3. Antithrombotic

 

 No, the demand did not change

33.0 (109)

 Yes, the demand increased

67.0 (221)

- Aspirin

54.8 (181)

- Enoxaparin

46.1 (152)

- Clopidogrel

9.4 (31)

- Heparin

5.2 (17)

- Warfarin

1.8 (6)

4. Anxiolytics and sedatives

 

 No, the drug demand was unchanged

29.4 (97)

 Yes, the demand increased

70.6 (233)

- Benzodiazepines

38.8 (128)

- Barbiturates

4.2 (14)

- Opioids

0.6 (2)

- Antidepressants

5.2 (17)

- Pregabalin

27.6 (91)

5. Antivirals (e.g., oseltamivir, acyclovir, amantadine)

 

 No, the demand did not change

70.7 (234)

 Yes, the demand increased

29.3 (97)

6. Antimalarials (e.g., hydroxychloroquine, chloroquine, artemether, etc.)

 

 No, the demand did not change

38.7 (128)

 Yes, the demand increased

61.3 (203)

7. Ondansetron (anti-emetic drug) demanded with one of the following medicines: antimalarial, macrolides, fluoroquinolone

 

 Yes

74.8 (247)

 No

13.6 (45)

Vitamins and supplements

 

 Yes

93.0 (307)

 No

7.0 (23)